Sandoz Chief Looks To Build On Recent Deals
CEO Richard Saynor Offers The Latest On Anti-Infectives, Generics And Biosimilars
With a number of recent deals under the firm’s belt in both generics and biosimilars, Sandoz CEO Richard Saynor talks to Generics Bulletin about how the firm is integrating new assets and building towards some key launches this year.
